Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06320626 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06320626 · ClinicalTrials.gov record · last posted 2024-03-20

Pharmacokinetic-guided Dosing of Emicizumab

Name: Pharmacokinetic-guided Dosing of Emicizumab — clinical trial record (NCT06320626)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DosEmi

StatusRecruiting

PhasePhase 4

SponsorKathelijn Fischer

Started2022-09-08

View on ClinicalTrials.gov ↗

Record status

This record was last updated March 20, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

from the ClinicalTrials.gov record

The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.

Trial Details

NCT Number	NCT06320626
Lead Sponsor	Kathelijn Fischer Collaborators: Erasmus Medical Center, Amsterdam University Medical Center, Leiden University Medical Center, Radboud University Medical Center, Maastricht University Medical Center, University Medical Center Groningen, HagaZiekenhuis, Dutch Society of Haemophilia Patients
Conditions	Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor, Hemophilia A, Severe, Adolescent, Child, Adult
Enrollment	95 participants
Start Date	2022-09-08
Primary Completion	2026-03 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2024-03-20